Lynparza approved in Japan for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer
60% of patients receiving Lynparza remained free of disease progression after three years vs. 27% receiving placebo in pivotal Phase III SOLO-1 trial AstraZeneca and MSD’s Lynparza is the only PARP inhibitor approved in JapanAstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, as detected by an approved companion diagnostic test. The approval by the